Renal metastasis of thyroid cancer is extremely rare. We report the case of a 62-year-old woman with Hürthle cell thyroid cancer (HCTC) with lungs, bones, and bilateral kidneys metastases. The renal metastatic lesions were clearly demonstrated by I whole body scan (WBS) with SPECT/CT. However, they exhibited false-negative results in F-FDG PET/CT, kidney ultrasonography, and contrast-enhanced CT scan. The findings imply that tumors have low glucose metabolism and are able to accumulate radioiodine, which is not commonly found in the relatively aggressive nature of HCTC. The patient received two sessions of 200 mCi I therapy within 6 months duration. There was complete treatment response as evaluated by the second post-therapeutic I SPECT/CT and serum thyroglobulin. To our knowledge, renal metastasis from HCTC with positive I but negative F-FDG uptake has not been reported in the literature. This case suggests that I SPECT/CT is useful for lesion localization and prediction of I therapy response.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567619 | PMC |
http://dx.doi.org/10.1007/s13139-016-0462-5 | DOI Listing |
Objective: The objective of this research was to devise and authenticate a predictive model that employs CT radiomics and deep learning methodologies for the accurate prediction of synchronous distant metastasis (SDM) in clear cell renal cell carcinoma (ccRCC).
Methods: A total of 143 ccRCC patients were included in the training cohort, and 62 ccRCC patients were included in the validation cohort. The CT images from all patients were normalized, and the tumor regions were manually segmented via ITK-SNAP software.
Cancers (Basel)
January 2025
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 W Holcombe Blvd., Houston, TX 77030, USA.
Predicting the behavior of clear cell renal cell carcinoma (ccRCC) is challenging using standard-of-care histopathologic examination. Indeed, pathologic RCC tumor grading, based on nuclear morphology, performs poorly in predicting outcomes of patients with International Society of Urological Pathology/World Health Organization grade 2 and 3 tumors, which account for most ccRCCs. We applied spatial point process modeling of H&E-stained images of patients with grade 2 and grade 3 ccRCCs ( = 72) to find optimum separation into two groups.
View Article and Find Full Text PDFClin Genitourin Cancer
December 2024
The Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA; The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Curr Oncol
December 2024
Saint-Petersburg State University, 199034 Saint-Petersburg, Russia.
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC).
Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.
Curr Oncol
December 2024
Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Vulvar cancer is one of the rarest gynecological malignancies. The development of this condition can be associated with either dysplasia linked to human papillomavirus (HPV), primarily affecting younger women, or vulvar dermatoses such as lichen sclerosus, which predominantly affect older women. Over the last decade, the incidence of vulvar cancer has risen by 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!